Maria Svelto,Giuseppe Procino,Monica Carmosino,Massimo Dal Monte,Paola Bagnoli
申请号：
US15513213
公开号：
US10149837B2
申请日:
2015.09.23
申请国别(地区):
US
年份:
2018
代理人:
摘要：
Object of the present invention is the use of selective agonists of beta-adrenergic type 3 receptors (BAR3) in the treatment of nephrogenic diabetes insipidus (NDI), in particular of X-linked nephrogenic diabetes insipidus (X-NDI).
